Source: Targeted Oncology, May 2025
The combination of melphalan and a hepatic delivery system (HDS) led to clinically meaningful efficacy vs best alternative care (BAC) in patients with unresectable metastatic uveal melanoma, according to data from the phase 3 FOCUS study (NCT02678572).
According to data published in Annals of Surgical Oncology and according to the trial’s efficacy analysis, melphalan and HDS demonstrated a favorable benefit-risk profile in this patient profile. Overall survival (OS), the trial’s primary end point, was numerically higher among those treated with melphalan plus HDS (n = 40) compared with patients treated with BAC (n = 32). In these respective arms, the median OS was 18.5 months vs 14.5 months, and at 1 and 2 years, the OS rates were 79% vs 67% and 27% vs 26%, respectively.